Peptide is a new treatment for influenza A virus

In a new study, researchers identified a peptide formed by antibodies that inhibits the activity of harmful bacteria such as virut influenza A and HIV-1.

Influenza A continues to cause emergencies, hospitalizations and deaths, especially for children and the elderly, and patients with poor resistance around the world. The emergence of avian influenza A virus and its ability to transmit human light have brought about a new concern about widespread disease.Although vaccines are an effective strategy for preventing influenza, researchers also focus on developing and finding antiviral drugs.

Virut influenza A. (Photo: drdavescience)

The decapepti (KP) kills the inner image of an enzyme-killing toxin (Pichia anomala) that works against pathogens. In the study, KP activity before influenza A virus was evaluated and the results showed that KP showed a significant inhibitory effect on the replication of two influenza A. influenza viruses. In addition, mice infected with influenza virus A injection of KP once a day for 10 days has a 40% increase in the residual wave rate and a significant reduction in the amount of virus in the lungs.

The researchers said: 'Overall, KP is a highly invasive anti-viral peptide that first exhibits a preventative action and has a good therapeutic effect on pathogens, HIV-1, and viruses. influenza A '.

Refer:
G. Conti, W. Magliani, S. Conti, L. Nencioni, R. Sgarbanti, AT Palamara, L. Polonelli.Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against the influenza A virus experimental infection.Antimicrobial Agents and Chemotherapy, 52. 12: 4331-4337